<DOC>
	<DOCNO>NCT00021320</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy without radiation therapy treat patient esophageal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy Treating Patients With Esophageal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine median two-year disease-free overall survival patient resectable esophageal cancer treat neoadjuvant paclitaxel , cisplatin , fluorouracil concurrent radiotherapy . - Determine complete partial response patient treat regimen . - Assess toxicity regimen patient . - Determine optimal dose paclitaxel administer regimen patient . - Determine effect tumor tubulin isoform expression chemosensitivity overall survival patient treat regimen . OUTLINE : Patients receive paclitaxel IV 3 hour cisplatin IV 1 hour day 1 . Treatment repeat every 3 week 2 course . Beginning 3 week completion initial chemotherapy , patient receive concurrent chemoradiotherapy comprise paclitaxel IV 1 hour cisplatin IV 1 hour day 1 , 8 , 15 , 22 , 29 ; fluorouracil IV continuously 5 week ; radiotherapy daily 5 day week 5 week . At 4-8 week completion chemoradiotherapy , patient may undergo surgical resection . Patients local progressive disease 2 course initial chemotherapy undergo surgical resection instead receive concurrent chemoradiotherapy . Patients follow within 6 week , every 3 month 3 year , annually 2 year . PROJECTED ACCRUAL : A total 14-30 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma , squamous cell , adenosquamous , undifferentiated carcinoma esophagus gastroesophageal junction Potentially resectable disease No malignant celiac node involvement No cervical esophageal carcinoma PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,800/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 3 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Other : No malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix No significant medical psychiatric illness would preclude study Not pregnant nursing Fertile patient must use effective contraception least 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy esophageal cancer Endocrine therapy : Not specify Radiotherapy : No prior thoracic radiotherapy Surgery : See Disease Characteristics No prior surgical resection esophageal tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>stage 0 esophageal cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>